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The primary vaginal T-cell non-Hodgkin lymphoma is a rare form of lymphoma.Most of the previously published cases were about
B-cell non-Hodgkin lymphomas. We present the case of a vaginal mass in an 82-year-old patient presenting vaginal bleeding. The
results of the immunohistological studies of the mass revealed the presence of a cytotoxic T-cell non-Hodgkin lymphoma, which
is the least common subtype.
1. Introduction
The primary affectation of the female genital tract in non-
Hodgkin lymphomas is rare and represents 1.5–2% of all
extraganglionar primary lymphomas. The most commonly
affected areas are in the ovaries (50%) and cervix, while the
uterine and vaginal affectation remains extremely rare (6%)
[1].
The average age of onset is in the fifth decade of life [2, 3]
and the most common histology is usually that of diffuse
large B-cell lymphoma (DLBCL). The patient’s motive for
consultation is usually due to abnormal vaginal bleeding [4].
Despite the lack of standard treatments for the non-
Hodgkin vaginal lymphoma, various treatment algorithms
are used which include chemotherapy and radiotherapy,
eliciting good results in initial stages of the disease [5].
We hereby present an unusual case of a vaginal T-cell
lymphoma. Most of the reported cases were of B-cell non-
Hodgkin lymphomas [1, 6].
2. Case Presentation
We present the case of an 82-year-old patient with no
personal history of interest that came for a consultation in our
gynecology department prompted by an episode of vaginal
bleeding lasting various days. Her obstetrical/gynecological
background includes 2 vaginal births and menopause at
the age of 50. During the exploration, we found a mass,
hard and friable in consistency, occupying the entire vaginal
cavity. We biopsied the tumor, and the histologic results
revealed the presence of medium-sized cells with granular
nuclei and vascular destruction accompanied by necrosis.
The immunohistochemistry showedCD3 (+), CD56 (−), CD8
(−), EBV (+), CD4(+), and granzyme B (+). The studies’
conclusions were that of a NK/cytotoxic T-cell extranodal
lymphoma (Figures 1 and 2).
A thoracoabdominal pelvic CT scan was performed,
confirming the solidmass described in our exploration: a 7.5×
7.5 × 9 cm mass with a rounded morphology, occupying the
vesical-uterine space. There were no pathological findings in
the uterus and ovaries. There was no sign of retroperitoneal
or pelvic lymphadenopathies, nor were there lesions at the
extrapelvic level (Figure 3). The Magnetic Resonance Imag-
ing (MRI) corroborated the findings at the vesical-uterine
level, whichwere previouslymentioned in the CT scan results
(Figure 4). The PET scan showed the previously discovered
mass in the vesical-uterine space, presenting a highmetabolic
activity (Figure 5).The rest of the studies showed no evidence
of increased tumor extension. The complete blood count
(CBC), LDH, B2 microglobulin, and albumin levels were
within the range of normality.
The patient rejected any type of treatment. She received
palliative care at home and died twomonths after having been
diagnosed.
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Figure 1: Tissue fragment where medium-sized cells and granular
nucleus are observed, along with vascular destruction. The images
on the left show Cd56 (−) and EBV (+) staining.
Figure 2: Visualization of positive Epstein-Barr staining.
3. Discussion
The Lymphomas are divided into two main categories:
Hodgkin lymphoma (HL) and non-Hodgkin lymphoma
(NHL). The latter is mainly currently divided into Precursor
Lymphoid Neoplasms, B-cell neoplasms, and mature T/NK-
Cell lymphomas. The incidence of non-Hodgkin lymphoma
is 2–5% of all cancers [7].
Primary NHL manifestation in the female genital tract is
extremely rare, with a prevalence ranging between 0.2 and
1.1%. Secondary affectation of the genital tract due to the
dissemination of a lymphoma is around 7–30% of all cases.
The most frequent location in extranodal NHL cases with
genital affectation is the ovaries, followed by the cervix and
uterus, and, lastly, themost unusual location is the vagina [8–
10]. The most common histological subtype of gynecological
lymphomas, primary or secondary, is the Large B-cell diffuse
lymphoma [11]. The cytotoxic T-cell NHL, such as the one
presented in our case, is extremely rare.
The incidence of extranodal lymphomas has increased
in the last decades [4]. This increase may be justified by
the association of different infectious agents, such as the
Epstein-Barr virus [12], the human immunodeficiency virus
[13, 14], immunosuppressive therapies [15], and exposure to
toxic substances and pollutants. Additionally, this increase
may be also related to the new diagnostic techniques which
keep on progressing [6, 12, 16].
Figure 3: CT scan demonstrating a largemass occupying the vaginal
cavity.
Figure 4: MRI demonstrating the vaginal lesion displacing the
uterus towards the cranial direction.
Figure 5: PET scan showing the mass in the vesical-uterine space.
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Table 1: Staging system for extranodal lymphomas. Modified Ann
Arbor classification.
Stage Description
IE Involvement of a single lymph node region or a singleorgan.
IIE
Involvement of a single extralymphatic organ or site
and one or more regional lymph nodes ipsilateral to
diaphragm.
IIE Involvement of a single extralymphatic organ or site andregional lymph nodes on both sides of the diaphragm.
IVE
Diffuse involvement or dissemination of one or more
extralymphatic sites, with or without the involvement of
lymphatic nodes.
The mean age at onset for NHL is 50 years, with most of
the women having entered menopause.
Themost common form of presentation of this neoplasm
is the abnormal vaginal bleeding; nevertheless, it may man-
ifest itself as abdominal or perineal pain, dyspareunia, dys-
menorrhea, and urethral obstruction [6]. It usually appears
as a large, fast growing and endophytic mass. In our case, the
patient consulted due to vaginal bleeding as the sole symptom
and it presented itself as an exophytic mass.
The diagnosis is confirmed by biopsy. The material
obtained through biopsy must be sufficient in order to
perform conventional histology and immunohistochemical
and molecular genetics studies to determine the lymphoma
subtype [6, 17, 18].
The most important prognostic factor for survival is the
tumor staging.TheModified Ann Arbor classification is used
for the extranodal NHL staging [19] (Table 1). According to
this classification, the case we have presented corresponds
to a stage IE. The majority of these tumors (75%) present
themselves in stages IE.
After the Ann Arbor classification, a prognostic index for
better survival was created for the extranodal NHL, which
was more widely accepted [20]. Namely, the International
Prognostic Index (IPI), which takes into account the age
of the patient, the stage (Ann Arbor classification), number
of extranodal sites affectation, the general condition of the
patient, and the LDH levels.
The prognosis for the vaginal lymphoma is encouraging,
with an mean survival of 5 years depending on the tumor
stages: 80% during the initial stages (I and II) and 30% in
advanced stages (III and IV) [1, 21].
The treatment of this type of tumor is not clearly estab-
lished because of its low incidence. Radiotherapy has been
used as the sole treatment in some cases, while chemotherapy
has been used in others [22]; nevertheless, it seems that
the combination of both treatments is the most accepted
alternative [5]. Surgery may also be used in treatment-
resistant cases associated with chemotherapy, although its
role is not generally accepted.
In our case, none of these treatment options were used
due to the patient’s refusal.
4. Conclusion
The incidence of the vaginal lymphoma is very low; however,
it can demonstrate early symptoms suggesting a gynecologic
neoplasm. Both gynecologist and pathologist must include
this disease in the differential diagnosis of a vaginalmass so as
to not delay or establish the wrong diagnosis that could lead
to failure to treat these patients.
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